Cure8 research brief
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted testing.
Clinicians treating patients with moderate–severe active ulcerative colitis, researchers studying biomarkers for infectious complications in IBD, and adult patients interested in how lab markers might guide diagnostic testing.
This single-center retrospective study included 82 adults with active UC who underwent colonic biopsy for CMV between 2018–2023; 28 (34%) were tissue-positive.
The authors report that the CALLY index had modest overall discrimination (AUC 0.601) but that a cutoff (≥2838) derived from their data was independently associated with tissue-confirmed CMV in multivariable analysis.
The study concludes the CALLY index alone has limited diagnostic performance but might add complementary information alongside clinical and inflammatory markers. Practical takeaway: The finding is hypothesis-generating rather than practice-changing.
It suggests the CALLY index could be explored as one component of a risk assessment for CMV testing in active UC, but it does not replace biopsy or established diagnostic methods.
This is a single-center, retrospective, cross-sectional study with a modest sample size and a cutoff derived from the same dataset; the structured content provided is an abstract-level summary, not a full independent review of the complete paper. The CALLY index showed only modest discrimination (AUC ~0.60) and the suggested cutoff needs external validation before clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
